NCT06269510 Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients
| NCT ID | NCT06269510 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Henry Ford Health System |
| Condition | Alcohol-related Liver Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 268 participants |
| Start Date | 2026-01-28 |
| Primary Completion | 2029-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 268 participants in total. It began in 2026-01-28 with a primary completion date of 2029-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this trial is to see if providing patients with alcohol-related liver disease with tailored alcohol use treatment options will increase engagement with treatment and correct possible misconceptions.
Eligibility Criteria
Inclusion Criteria: * Willingness to comply with all study procedures and availability for the duration of the study * Willing and able to provide informed consent * Enrolled at University of Michigan (UM) hepatology clinics or inpatients at UM Hospitals * Documented diagnosis of alcohol-related liver disease (ALD) (per protocol) * Recent alcohol use of any amount within the past 6 months as assessed by either patient interview, medical chart review, or positive alcohol biomarker (e.g. blood alcohol level, urinary ethyl glucuronide, urinary ethyl sulfate, or phosphatidylethanol) in the medical record. * No alcohol use treatment within the past 1 month including, but not limited to: * Any professionally lead therapy with a mental health counselor (such as, one-on-one therapy, group therapy, couples or family therapy) with a primary aim of alcohol abstinence or reduction in alcohol use. * Community-based alcohol recovery groups (such as, Alcoholics Anonymous, SMART Recovery, Celebrate Recovery, Refuge Recovery) * Community-based church support groups primarily focused on alcohol abstinence or reduction in use. * Residential (inpatient) alcohol treatment * Intensive outpatient programs * Any telehealth version of the above options * Access to a Smartphone or computer for purposes of follow-up. Those who do not have a Smartphone will be provided one along with a calling/data plan at no cost to subject by the study team for the duration of the research stud. * Ability to speak and comprehend English Exclusion Criteria: * Unable to provide voluntary informed consent for any reason * Substantially cognitively impaired as evidenced by Westhaven grade 2 or higher hepatic encephalopathy or a score \>=10 on the Short Blessed Test for cognitive impairment. * Unable to read or understand English * Undergoing active evaluation for liver transplantation, is listed for liver transplant, or is post-transplantation * Is enrolled in the multidisciplinary ALD clinic at Michigan Medicine * Any other medical condition or circumstance that precludes safe and meaningful participation in the study * History of nonadherence to previous clinical or research studies
Contact & Investigator
Jessica Mellinger, MD, MSc
PRINCIPAL INVESTIGATOR
Henry Ford Health System
Frequently Asked Questions
Who can join the NCT06269510 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Alcohol-related Liver Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06269510 currently recruiting?
Yes, NCT06269510 is actively recruiting participants. Contact the research team at mmelica1@hfhs.org for enrollment information.
Where is the NCT06269510 trial being conducted?
This trial is being conducted at Detroit, United States.
Who is sponsoring the NCT06269510 clinical trial?
NCT06269510 is sponsored by Henry Ford Health System. The principal investigator is Jessica Mellinger, MD, MSc at Henry Ford Health System. The trial plans to enroll 268 participants.